A Phase I, Multi-center, Open-label, Single-dose Escalation and Expansion, Dose Escalation and Expansion Combination With Chemotherapy Study Evaluating the Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
Latest Information Update: 08 Jul 2024
At a glance
- Drugs M 108 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors FutureGen Biopharmaceutical
- 04 Jun 2024 Results (As of January 15, 2024, n=31 )presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 11 Sep 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 11 Sep 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jul 2024.